Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stomatitis | 115 | 2024 | 271 | 23.910 |
Why?
|
Mucositis | 21 | 2024 | 108 | 5.230 |
Why?
|
Head and Neck Neoplasms | 47 | 2024 | 2891 | 5.030 |
Why?
|
Radiation Injuries | 25 | 2024 | 1185 | 5.000 |
Why?
|
Mouth Mucosa | 65 | 2021 | 430 | 4.300 |
Why?
|
Antineoplastic Agents | 69 | 2024 | 13616 | 3.100 |
Why?
|
Radiotherapy | 30 | 2019 | 1498 | 2.880 |
Why?
|
Mouth Neoplasms | 12 | 2021 | 595 | 2.220 |
Why?
|
Organometallic Compounds | 6 | 2023 | 649 | 1.840 |
Why?
|
Oral Ulcer | 9 | 2021 | 96 | 1.830 |
Why?
|
Periodontitis | 4 | 2023 | 559 | 1.430 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2023 | 710 | 1.430 |
Why?
|
Neoplasms | 46 | 2023 | 22083 | 1.390 |
Why?
|
Mouth Diseases | 20 | 2016 | 242 | 1.370 |
Why?
|
Taxoids | 2 | 2023 | 666 | 1.330 |
Why?
|
Gastrointestinal Diseases | 8 | 2018 | 1197 | 1.280 |
Why?
|
Superoxide Dismutase | 6 | 2023 | 592 | 1.250 |
Why?
|
Xerostomia | 9 | 2022 | 94 | 1.230 |
Why?
|
Radiation Injuries, Experimental | 7 | 2014 | 88 | 1.150 |
Why?
|
Pneumonia, Ventilator-Associated | 2 | 2021 | 279 | 1.110 |
Why?
|
Oral Medicine | 3 | 2024 | 36 | 1.110 |
Why?
|
Oligonucleotide Array Sequence Analysis | 8 | 2017 | 3777 | 1.010 |
Why?
|
Radiation-Protective Agents | 5 | 2019 | 88 | 0.960 |
Why?
|
Oropharyngeal Neoplasms | 5 | 2021 | 491 | 0.960 |
Why?
|
Fatigue | 3 | 2017 | 1550 | 0.860 |
Why?
|
Diarrhea | 4 | 2014 | 1319 | 0.860 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2024 | 857 | 0.860 |
Why?
|
Drug Design | 3 | 2018 | 1050 | 0.820 |
Why?
|
Cyclosporins | 1 | 2022 | 216 | 0.800 |
Why?
|
Lichen Planus, Oral | 1 | 2022 | 56 | 0.780 |
Why?
|
Tooth Loss | 1 | 2022 | 199 | 0.730 |
Why?
|
Cricetinae | 25 | 2016 | 2427 | 0.730 |
Why?
|
Carcinoma, Squamous Cell | 10 | 2018 | 4020 | 0.730 |
Why?
|
Hematopoietic Stem Cell Transplantation | 12 | 2021 | 5663 | 0.700 |
Why?
|
Free Radical Scavengers | 1 | 2021 | 211 | 0.690 |
Why?
|
Probiotics | 1 | 2024 | 378 | 0.690 |
Why?
|
Interleukin-11 | 6 | 2002 | 58 | 0.690 |
Why?
|
Mesocricetus | 19 | 2016 | 252 | 0.690 |
Why?
|
Oral Health | 3 | 2023 | 487 | 0.670 |
Why?
|
Fibroblast Growth Factor 7 | 7 | 2015 | 59 | 0.670 |
Why?
|
Humans | 212 | 2024 | 760437 | 0.650 |
Why?
|
Sirolimus | 6 | 2014 | 1533 | 0.640 |
Why?
|
Dipeptides | 2 | 2011 | 391 | 0.640 |
Why?
|
Mouth | 7 | 2021 | 380 | 0.630 |
Why?
|
Hematologic Neoplasms | 4 | 2023 | 1890 | 0.600 |
Why?
|
Fluorouracil | 14 | 2014 | 1637 | 0.600 |
Why?
|
Leukoplakia, Oral | 1 | 2018 | 77 | 0.580 |
Why?
|
Drugs, Investigational | 2 | 2018 | 212 | 0.580 |
Why?
|
Cost of Illness | 3 | 2024 | 1931 | 0.540 |
Why?
|
Leukemia | 6 | 2023 | 1522 | 0.530 |
Why?
|
Periodontal Diseases | 7 | 2015 | 451 | 0.500 |
Why?
|
Biological Products | 1 | 2024 | 911 | 0.480 |
Why?
|
Fatigue Syndrome, Chronic | 1 | 2016 | 215 | 0.480 |
Why?
|
Psoriasis | 1 | 2023 | 937 | 0.470 |
Why?
|
Spectrum Analysis, Raman | 2 | 2014 | 237 | 0.470 |
Why?
|
Transplantation Conditioning | 3 | 2017 | 1588 | 0.460 |
Why?
|
Mucous Membrane | 5 | 2014 | 657 | 0.460 |
Why?
|
Melphalan | 2 | 2007 | 420 | 0.460 |
Why?
|
Inflammation | 12 | 2021 | 10746 | 0.450 |
Why?
|
Camptothecin | 4 | 2014 | 590 | 0.450 |
Why?
|
Stomatitis, Aphthous | 4 | 2013 | 51 | 0.440 |
Why?
|
Genomics | 5 | 2017 | 5806 | 0.430 |
Why?
|
Phenotype | 7 | 2023 | 16585 | 0.430 |
Why?
|
Bayes Theorem | 5 | 2020 | 2326 | 0.430 |
Why?
|
Cytokines | 12 | 2021 | 7377 | 0.430 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2023 | 15867 | 0.420 |
Why?
|
Osteoradionecrosis | 4 | 2017 | 51 | 0.420 |
Why?
|
Oral Hygiene | 5 | 2020 | 129 | 0.420 |
Why?
|
Health Care Costs | 5 | 2022 | 3240 | 0.410 |
Why?
|
Anti-Inflammatory Agents | 8 | 2016 | 1807 | 0.400 |
Why?
|
Colorectal Neoplasms | 5 | 2015 | 6894 | 0.400 |
Why?
|
Burning Mouth Syndrome | 3 | 2017 | 25 | 0.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2019 | 11729 | 0.380 |
Why?
|
Jaw Diseases | 3 | 2009 | 92 | 0.380 |
Why?
|
Disease Models, Animal | 17 | 2021 | 18216 | 0.380 |
Why?
|
Toll-Like Receptor 4 | 1 | 2014 | 579 | 0.370 |
Why?
|
Cranial Irradiation | 4 | 2009 | 390 | 0.370 |
Why?
|
Dexamethasone | 3 | 2022 | 1944 | 0.360 |
Why?
|
Dental Care for Disabled | 5 | 1993 | 24 | 0.350 |
Why?
|
Nausea | 1 | 2013 | 679 | 0.350 |
Why?
|
Radiodermatitis | 2 | 2024 | 58 | 0.350 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2805 | 0.350 |
Why?
|
Vomiting | 1 | 2013 | 652 | 0.350 |
Why?
|
Bone Marrow Transplantation | 8 | 2002 | 2693 | 0.350 |
Why?
|
Genetic Markers | 1 | 2016 | 2612 | 0.350 |
Why?
|
TOR Serine-Threonine Kinases | 6 | 2017 | 2058 | 0.340 |
Why?
|
Tumor Necrosis Factors | 1 | 2010 | 107 | 0.340 |
Why?
|
Genome-Wide Association Study | 4 | 2023 | 12653 | 0.340 |
Why?
|
Proteomics | 1 | 2023 | 3818 | 0.340 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 3 | 2009 | 318 | 0.340 |
Why?
|
Animals | 77 | 2021 | 168253 | 0.340 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1024 | 0.340 |
Why?
|
Dental Care for Chronically Ill | 1 | 2009 | 32 | 0.330 |
Why?
|
Robotics | 1 | 2016 | 819 | 0.330 |
Why?
|
Gene Expression Profiling | 6 | 2016 | 9410 | 0.330 |
Why?
|
Breast Neoplasms | 7 | 2024 | 20985 | 0.330 |
Why?
|
Dental Care | 2 | 2024 | 285 | 0.320 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5143 | 0.320 |
Why?
|
Genetic Predisposition to Disease | 7 | 2023 | 17854 | 0.320 |
Why?
|
Sepsis | 1 | 2023 | 2583 | 0.320 |
Why?
|
Neuroglia | 1 | 2014 | 955 | 0.320 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2024 | 628 | 0.310 |
Why?
|
Oxidative Stress | 6 | 2021 | 3108 | 0.310 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2017 | 1640 | 0.310 |
Why?
|
Saliva | 5 | 2013 | 827 | 0.310 |
Why?
|
Treatment Outcome | 28 | 2024 | 64591 | 0.310 |
Why?
|
NF-kappa B | 9 | 2014 | 2485 | 0.310 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2018 | 2821 | 0.310 |
Why?
|
Drug Discovery | 1 | 2016 | 1054 | 0.310 |
Why?
|
Peptide Hormones | 3 | 2016 | 132 | 0.300 |
Why?
|
Cisplatin | 3 | 2022 | 1647 | 0.300 |
Why?
|
Computational Biology | 3 | 2017 | 3510 | 0.300 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2010 | 321 | 0.290 |
Why?
|
Precancerous Conditions | 2 | 2014 | 978 | 0.290 |
Why?
|
Administration, Topical | 5 | 2022 | 703 | 0.290 |
Why?
|
Clonazepam | 2 | 2017 | 135 | 0.280 |
Why?
|
Arthritis, Rheumatoid | 1 | 2022 | 3759 | 0.280 |
Why?
|
Genotype | 3 | 2023 | 12976 | 0.280 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5421 | 0.270 |
Why?
|
Nutrition Surveys | 3 | 2023 | 1726 | 0.270 |
Why?
|
Immunologic Factors | 3 | 2021 | 1588 | 0.270 |
Why?
|
Clinical Trials as Topic | 9 | 2023 | 7996 | 0.270 |
Why?
|
Osteonecrosis | 1 | 2008 | 229 | 0.270 |
Why?
|
Treponema | 1 | 2006 | 38 | 0.270 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2860 | 0.270 |
Why?
|
Gingiva | 3 | 2006 | 407 | 0.270 |
Why?
|
Female | 95 | 2024 | 391875 | 0.260 |
Why?
|
Inflammation Mediators | 4 | 2021 | 1886 | 0.260 |
Why?
|
Transforming Growth Factor beta | 4 | 2001 | 1959 | 0.260 |
Why?
|
Fumonisins | 1 | 2005 | 10 | 0.260 |
Why?
|
Doxorubicin | 1 | 2013 | 2215 | 0.260 |
Why?
|
Signal Transduction | 7 | 2021 | 23397 | 0.260 |
Why?
|
Male | 106 | 2024 | 360035 | 0.260 |
Why?
|
Triamcinolone | 3 | 2022 | 68 | 0.260 |
Why?
|
Placebos | 9 | 2019 | 1661 | 0.260 |
Why?
|
Porphyromonas gingivalis | 1 | 2006 | 162 | 0.250 |
Why?
|
Antibodies, Monoclonal | 2 | 2014 | 9176 | 0.250 |
Why?
|
Fibroblast Growth Factors | 3 | 2008 | 867 | 0.250 |
Why?
|
Blood Cells | 3 | 2006 | 305 | 0.240 |
Why?
|
Dental Plaque | 1 | 2006 | 209 | 0.240 |
Why?
|
Gene Regulatory Networks | 3 | 2020 | 1739 | 0.240 |
Why?
|
Tongue | 2 | 2006 | 403 | 0.240 |
Why?
|
Quinazolinones | 2 | 2017 | 221 | 0.240 |
Why?
|
Middle Aged | 65 | 2024 | 220382 | 0.240 |
Why?
|
Severity of Illness Index | 14 | 2021 | 15820 | 0.240 |
Why?
|
Focal Infection, Dental | 3 | 2009 | 26 | 0.240 |
Why?
|
Epidermal Growth Factor | 2 | 2000 | 700 | 0.230 |
Why?
|
Hyperbaric Oxygenation | 3 | 2017 | 165 | 0.230 |
Why?
|
Trismus | 2 | 2022 | 33 | 0.230 |
Why?
|
Ceramides | 1 | 2005 | 200 | 0.230 |
Why?
|
General Practice, Dental | 3 | 2015 | 33 | 0.230 |
Why?
|
Prostatic Neoplasms | 2 | 2017 | 11095 | 0.230 |
Why?
|
Apoptosis | 10 | 2017 | 9468 | 0.230 |
Why?
|
Combined Modality Therapy | 9 | 2009 | 8522 | 0.230 |
Why?
|
Risk Factors | 19 | 2023 | 74055 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2017 | 10759 | 0.220 |
Why?
|
Models, Biological | 5 | 2017 | 9462 | 0.220 |
Why?
|
Intestinal Mucosa | 6 | 2008 | 3026 | 0.220 |
Why?
|
Diphosphonates | 1 | 2008 | 636 | 0.220 |
Why?
|
Oxidoreductases | 1 | 2005 | 412 | 0.220 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2007 | 617 | 0.220 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2003 | 643 | 0.210 |
Why?
|
Tacrolimus | 3 | 2022 | 733 | 0.210 |
Why?
|
Xenobiotics | 1 | 2023 | 70 | 0.210 |
Why?
|
Tretinoin | 2 | 2023 | 519 | 0.210 |
Why?
|
Fluocinonide | 1 | 2022 | 9 | 0.210 |
Why?
|
Bandages | 1 | 2024 | 269 | 0.210 |
Why?
|
Glycosyltransferases | 1 | 2023 | 117 | 0.200 |
Why?
|
Double-Blind Method | 11 | 2021 | 12320 | 0.200 |
Why?
|
Isoenzymes | 2 | 2004 | 1688 | 0.200 |
Why?
|
Adult | 60 | 2024 | 220781 | 0.200 |
Why?
|
Drug Approval | 2 | 2023 | 811 | 0.200 |
Why?
|
Clobetasol | 1 | 2022 | 33 | 0.200 |
Why?
|
Principal Component Analysis | 2 | 2017 | 943 | 0.200 |
Why?
|
Imidazoles | 1 | 2008 | 1179 | 0.200 |
Why?
|
Lactococcus lactis | 2 | 2013 | 29 | 0.200 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2019 | 801 | 0.200 |
Why?
|
Gastroenteritis | 1 | 2004 | 236 | 0.200 |
Why?
|
Algorithms | 3 | 2020 | 14002 | 0.200 |
Why?
|
Amifostine | 4 | 2015 | 40 | 0.200 |
Why?
|
Azetidines | 1 | 2023 | 140 | 0.190 |
Why?
|
Graft vs Host Disease | 8 | 2014 | 3028 | 0.190 |
Why?
|
Costs and Cost Analysis | 2 | 2023 | 1668 | 0.190 |
Why?
|
Caspases | 1 | 2004 | 876 | 0.190 |
Why?
|
Quality of Life | 11 | 2021 | 13338 | 0.190 |
Why?
|
Antioxidants | 2 | 2008 | 1670 | 0.190 |
Why?
|
Reactive Oxygen Species | 3 | 2014 | 2137 | 0.180 |
Why?
|
Bone Density Conservation Agents | 1 | 2008 | 795 | 0.180 |
Why?
|
Toothbrushing | 1 | 2021 | 46 | 0.180 |
Why?
|
Bacteremia | 2 | 2017 | 979 | 0.180 |
Why?
|
Mouthwashes | 5 | 2017 | 57 | 0.180 |
Why?
|
Aged | 33 | 2024 | 168840 | 0.170 |
Why?
|
Receptors, Pattern Recognition | 1 | 2021 | 83 | 0.170 |
Why?
|
Oropharynx | 1 | 2000 | 138 | 0.170 |
Why?
|
Flavonoids | 1 | 2023 | 444 | 0.170 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2870 | 0.170 |
Why?
|
Carcinoma | 2 | 2013 | 2328 | 0.160 |
Why?
|
Steroids | 2 | 2022 | 928 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8519 | 0.160 |
Why?
|
Prognosis | 6 | 2021 | 29551 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.160 |
Why?
|
Clonidine | 1 | 2019 | 169 | 0.160 |
Why?
|
Protective Agents | 2 | 2014 | 150 | 0.160 |
Why?
|
Prevalence | 3 | 2023 | 15698 | 0.160 |
Why?
|
United States | 11 | 2024 | 72202 | 0.160 |
Why?
|
Lung Neoplasms | 6 | 2024 | 13312 | 0.160 |
Why?
|
Dental Service, Hospital | 3 | 1983 | 5 | 0.150 |
Why?
|
Retrospective Studies | 22 | 2024 | 80430 | 0.150 |
Why?
|
Pancreatic Neoplasms | 2 | 2015 | 5359 | 0.150 |
Why?
|
Protein Kinase C | 1 | 2023 | 1202 | 0.150 |
Why?
|
Cyclooxygenase 2 | 3 | 2006 | 597 | 0.150 |
Why?
|
Uncertainty | 1 | 2023 | 753 | 0.150 |
Why?
|
Reproducibility of Results | 5 | 2023 | 20078 | 0.150 |
Why?
|
Dental Caries | 2 | 2021 | 421 | 0.140 |
Why?
|
Growth Inhibitors | 1 | 1998 | 378 | 0.140 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1790 | 0.140 |
Why?
|
Administration, Mucosal | 1 | 2016 | 6 | 0.140 |
Why?
|
Stomatognathic Diseases | 1 | 1996 | 22 | 0.140 |
Why?
|
Specialties, Dental | 3 | 2015 | 35 | 0.140 |
Why?
|
Thermography | 2 | 1987 | 63 | 0.140 |
Why?
|
Paresthesia | 1 | 2017 | 162 | 0.130 |
Why?
|
Insurance, Health | 2 | 2019 | 2491 | 0.130 |
Why?
|
Parenteral Nutrition, Total | 3 | 2011 | 304 | 0.130 |
Why?
|
Tight Junctions | 2 | 2016 | 322 | 0.130 |
Why?
|
Research | 2 | 2021 | 1977 | 0.130 |
Why?
|
Databases, Nucleic Acid | 1 | 2017 | 204 | 0.130 |
Why?
|
ROC Curve | 2 | 2014 | 3571 | 0.130 |
Why?
|
Tissue Culture Techniques | 1 | 2017 | 290 | 0.130 |
Why?
|
9,10-Dimethyl-1,2-benzanthracene | 3 | 2009 | 58 | 0.130 |
Why?
|
Gastric Mucosa | 3 | 2007 | 600 | 0.130 |
Why?
|
Ulcer | 8 | 1994 | 204 | 0.130 |
Why?
|
Stem Cell Transplantation | 3 | 2014 | 1598 | 0.120 |
Why?
|
Epithelial Cells | 5 | 2012 | 3661 | 0.120 |
Why?
|
World Health Organization | 1 | 2021 | 1315 | 0.120 |
Why?
|
United States Food and Drug Administration | 1 | 2023 | 1663 | 0.120 |
Why?
|
Enzyme Inhibitors | 1 | 2005 | 3710 | 0.120 |
Why?
|
Myositis, Inclusion Body | 1 | 2016 | 145 | 0.120 |
Why?
|
Anti-Ulcer Agents | 2 | 2014 | 112 | 0.120 |
Why?
|
Gingivitis, Necrotizing Ulcerative | 3 | 2010 | 15 | 0.120 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2015 | 110 | 0.120 |
Why?
|
Risk Assessment | 5 | 2015 | 23953 | 0.110 |
Why?
|
Proctitis | 1 | 2014 | 41 | 0.110 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2017 | 649 | 0.110 |
Why?
|
Propylene Glycols | 2 | 2005 | 91 | 0.110 |
Why?
|
Triterpenes | 1 | 2014 | 76 | 0.110 |
Why?
|
Genetic Techniques | 1 | 2016 | 427 | 0.110 |
Why?
|
Interleukin-8 | 1 | 2017 | 696 | 0.110 |
Why?
|
Aromatase Inhibitors | 1 | 2017 | 511 | 0.110 |
Why?
|
Periapical Diseases | 1 | 1993 | 21 | 0.110 |
Why?
|
Radiotherapy Dosage | 3 | 2019 | 2898 | 0.110 |
Why?
|
Administration, Oral | 2 | 2021 | 4010 | 0.110 |
Why?
|
Streptococcal Infections | 1 | 1998 | 616 | 0.110 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26063 | 0.110 |
Why?
|
Pharmacogenetics | 2 | 2015 | 675 | 0.110 |
Why?
|
Arthralgia | 1 | 2017 | 463 | 0.110 |
Why?
|
Wound Healing | 6 | 2006 | 2799 | 0.110 |
Why?
|
Oleanolic Acid | 1 | 2013 | 43 | 0.110 |
Why?
|
Physical Examination | 1 | 2019 | 1254 | 0.110 |
Why?
|
Neoplasm Staging | 4 | 2017 | 11096 | 0.110 |
Why?
|
Cell Death | 2 | 2010 | 1664 | 0.110 |
Why?
|
Disease Management | 2 | 2021 | 2501 | 0.110 |
Why?
|
Databases, Genetic | 1 | 2020 | 1738 | 0.110 |
Why?
|
Interleukin-6 | 5 | 2017 | 3209 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 6 | 2016 | 1337 | 0.110 |
Why?
|
Immunosuppressive Agents | 3 | 2014 | 4168 | 0.110 |
Why?
|
Organoplatinum Compounds | 1 | 2014 | 407 | 0.100 |
Why?
|
Esophagitis | 1 | 2014 | 164 | 0.100 |
Why?
|
Oral Hemorrhage | 5 | 2008 | 24 | 0.100 |
Why?
|
Leucovorin | 1 | 2014 | 642 | 0.100 |
Why?
|
Fibrosarcoma | 5 | 1989 | 308 | 0.100 |
Why?
|
Software | 2 | 2016 | 4426 | 0.100 |
Why?
|
Education, Dental, Continuing | 1 | 1991 | 9 | 0.100 |
Why?
|
Mice, Inbred ICR | 1 | 2013 | 364 | 0.100 |
Why?
|
Tongue Neoplasms | 1 | 2014 | 183 | 0.100 |
Why?
|
Organs at Risk | 1 | 2014 | 359 | 0.100 |
Why?
|
Cell Division | 6 | 2016 | 4461 | 0.100 |
Why?
|
Peptide Fragments | 3 | 2016 | 5105 | 0.100 |
Why?
|
Inpatients | 2 | 2023 | 2545 | 0.100 |
Why?
|
Methotrexate | 6 | 2008 | 1720 | 0.100 |
Why?
|
Bone Substitutes | 2 | 2005 | 236 | 0.100 |
Why?
|
Receptors, Notch | 1 | 2017 | 743 | 0.100 |
Why?
|
Artificial Intelligence | 2 | 2016 | 2568 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2014 | 716 | 0.100 |
Why?
|
Radiation Dosage | 2 | 2011 | 1958 | 0.100 |
Why?
|
Survival Analysis | 4 | 2020 | 10075 | 0.100 |
Why?
|
Boston | 5 | 2017 | 9326 | 0.100 |
Why?
|
Absorbable Implants | 2 | 2005 | 338 | 0.100 |
Why?
|
Cryotherapy | 3 | 2014 | 159 | 0.100 |
Why?
|
Length of Stay | 4 | 2011 | 6413 | 0.090 |
Why?
|
Ethylenediamines | 1 | 2011 | 57 | 0.090 |
Why?
|
Androstadienes | 1 | 2013 | 348 | 0.090 |
Why?
|
Epithelium | 7 | 2008 | 1603 | 0.090 |
Why?
|
Pain | 3 | 2020 | 5075 | 0.090 |
Why?
|
Molecular Biology | 2 | 2006 | 580 | 0.090 |
Why?
|
Rats | 17 | 2013 | 23712 | 0.090 |
Why?
|
Immunity, Innate | 2 | 2018 | 3059 | 0.090 |
Why?
|
Bone Transplantation | 3 | 2005 | 926 | 0.090 |
Why?
|
Oligopeptides | 1 | 2016 | 1186 | 0.090 |
Why?
|
Tongue Diseases | 4 | 1987 | 68 | 0.090 |
Why?
|
Bone Regeneration | 2 | 2005 | 432 | 0.090 |
Why?
|
Free Radicals | 2 | 2008 | 238 | 0.090 |
Why?
|
Anesthesia, Dental | 1 | 1991 | 64 | 0.090 |
Why?
|
Australia | 1 | 2014 | 1245 | 0.090 |
Why?
|
Gingival Crevicular Fluid | 1 | 2010 | 94 | 0.090 |
Why?
|
Misoprostol | 1 | 2011 | 93 | 0.090 |
Why?
|
Time Factors | 16 | 2019 | 39947 | 0.090 |
Why?
|
Murinae | 1 | 2010 | 18 | 0.090 |
Why?
|
Bacterial Infections | 5 | 2006 | 1406 | 0.090 |
Why?
|
Prospective Studies | 5 | 2020 | 54339 | 0.090 |
Why?
|
Pharyngeal Diseases | 1 | 1991 | 134 | 0.090 |
Why?
|
Pyrazoles | 2 | 2014 | 2007 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4903 | 0.090 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1610 | 0.080 |
Why?
|
Immunity, Cellular | 4 | 1976 | 1559 | 0.080 |
Why?
|
Bone Marrow | 3 | 1995 | 2907 | 0.080 |
Why?
|
Cyanoacrylates | 3 | 1975 | 46 | 0.080 |
Why?
|
Interleukin-1beta | 3 | 2010 | 997 | 0.080 |
Why?
|
Immunohistochemistry | 6 | 2008 | 11070 | 0.080 |
Why?
|
Gingival Overgrowth | 1 | 2009 | 7 | 0.080 |
Why?
|
Jaw | 2 | 2017 | 93 | 0.080 |
Why?
|
Hospitalization | 3 | 2017 | 10698 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 1517 | 0.080 |
Why?
|
HMGB1 Protein | 1 | 2010 | 137 | 0.080 |
Why?
|
Anti-Infective Agents | 3 | 2014 | 984 | 0.080 |
Why?
|
Benzydamine | 2 | 2006 | 3 | 0.080 |
Why?
|
Drug Delivery Systems | 2 | 2016 | 2224 | 0.080 |
Why?
|
Area Under Curve | 1 | 2013 | 1633 | 0.080 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2009 | 105 | 0.080 |
Why?
|
Periodontal Pocket | 2 | 2006 | 167 | 0.080 |
Why?
|
Anesthesia, Local | 1 | 1991 | 277 | 0.080 |
Why?
|
Incidence | 4 | 2020 | 21322 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2015 | 3596 | 0.080 |
Why?
|
Canada | 1 | 2014 | 2119 | 0.080 |
Why?
|
Leukocyte Count | 6 | 1993 | 1596 | 0.080 |
Why?
|
Maxillary Diseases | 1 | 2008 | 48 | 0.080 |
Why?
|
Clinical Protocols | 1 | 2014 | 1438 | 0.080 |
Why?
|
Alveolar Process | 4 | 2005 | 294 | 0.080 |
Why?
|
Interferon-gamma | 1 | 2017 | 3157 | 0.080 |
Why?
|
Transplantation, Autologous | 2 | 2007 | 2113 | 0.080 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 326 | 0.080 |
Why?
|
Aged, 80 and over | 9 | 2019 | 58859 | 0.080 |
Why?
|
Multigene Family | 1 | 2011 | 1077 | 0.080 |
Why?
|
Forecasting | 2 | 2013 | 2925 | 0.080 |
Why?
|
Up-Regulation | 3 | 2014 | 4116 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5296 | 0.070 |
Why?
|
Critical Illness | 1 | 2021 | 2722 | 0.070 |
Why?
|
Phosphoproteins | 1 | 2017 | 2444 | 0.070 |
Why?
|
Mandibular Diseases | 1 | 2008 | 119 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2011 | 6230 | 0.070 |
Why?
|
Abscess | 1 | 1991 | 606 | 0.070 |
Why?
|
Skin Diseases | 1 | 2016 | 1090 | 0.070 |
Why?
|
Blood Cell Count | 2 | 1997 | 397 | 0.070 |
Why?
|
Europe | 1 | 2014 | 3419 | 0.070 |
Why?
|
Host-Pathogen Interactions | 1 | 2016 | 1454 | 0.070 |
Why?
|
Genetic Association Studies | 1 | 2017 | 2723 | 0.070 |
Why?
|
Mice | 26 | 2021 | 81402 | 0.070 |
Why?
|
Keratinocytes | 1 | 2011 | 790 | 0.070 |
Why?
|
Clone Cells | 1 | 2010 | 1660 | 0.070 |
Why?
|
Diffusion of Innovation | 1 | 1991 | 726 | 0.070 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2013 | 1115 | 0.070 |
Why?
|
Carcinogens | 1 | 2009 | 451 | 0.070 |
Why?
|
Single-Blind Method | 1 | 2010 | 1571 | 0.070 |
Why?
|
Transplantation, Homologous | 6 | 2006 | 4808 | 0.070 |
Why?
|
Antineoplastic Protocols | 1 | 2006 | 48 | 0.070 |
Why?
|
Polymers | 2 | 2005 | 1615 | 0.070 |
Why?
|
Healthcare Disparities | 2 | 2019 | 3344 | 0.070 |
Why?
|
Digestive System | 1 | 2007 | 244 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 6 | 2012 | 4355 | 0.070 |
Why?
|
Drug Therapy | 1 | 2009 | 503 | 0.070 |
Why?
|
Models, Genetic | 1 | 2016 | 3445 | 0.070 |
Why?
|
Models, Chemical | 1 | 2008 | 611 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2017 | 1934 | 0.070 |
Why?
|
Injections, Intravenous | 1 | 2008 | 1379 | 0.070 |
Why?
|
Periodontal Index | 1 | 2006 | 151 | 0.070 |
Why?
|
Benzhydryl Compounds | 1 | 2013 | 916 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2013 | 15257 | 0.060 |
Why?
|
Bone Resorption | 3 | 1988 | 723 | 0.060 |
Why?
|
Neoplasms, Experimental | 5 | 1981 | 1228 | 0.060 |
Why?
|
Reference Values | 2 | 2006 | 4921 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2017 | 3610 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2004 | 263 | 0.060 |
Why?
|
Markov Chains | 1 | 2009 | 965 | 0.060 |
Why?
|
Manganese | 1 | 2008 | 395 | 0.060 |
Why?
|
Bacterial Typing Techniques | 1 | 2006 | 264 | 0.060 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2016 | 1468 | 0.060 |
Why?
|
Medical Audit | 1 | 2006 | 453 | 0.060 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2005 | 82 | 0.060 |
Why?
|
Melanoma | 1 | 2024 | 5704 | 0.060 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4735 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4849 | 0.060 |
Why?
|
Mutation | 4 | 2017 | 30025 | 0.060 |
Why?
|
Research Design | 1 | 2001 | 6168 | 0.060 |
Why?
|
Behavior, Animal | 1 | 2013 | 1877 | 0.060 |
Why?
|
Caspases, Initiator | 1 | 2004 | 31 | 0.060 |
Why?
|
Bone Diseases, Metabolic | 1 | 2008 | 409 | 0.060 |
Why?
|
Genes, Neoplasm | 1 | 2006 | 370 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1973 | 0.060 |
Why?
|
Cohort Studies | 7 | 2017 | 41366 | 0.060 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2005 | 213 | 0.060 |
Why?
|
Recurrence | 2 | 2013 | 8466 | 0.060 |
Why?
|
Premedication | 1 | 2005 | 247 | 0.060 |
Why?
|
Antigen-Antibody Complex | 4 | 1982 | 513 | 0.060 |
Why?
|
Medical Oncology | 1 | 2016 | 2318 | 0.060 |
Why?
|
Nerve Block | 1 | 1991 | 704 | 0.060 |
Why?
|
Preoperative Care | 1 | 1993 | 2242 | 0.060 |
Why?
|
Proteins | 4 | 2003 | 6033 | 0.060 |
Why?
|
Medicaid | 1 | 2017 | 2810 | 0.060 |
Why?
|
Whole-Body Irradiation | 1 | 2005 | 433 | 0.060 |
Why?
|
Antibiotic Prophylaxis | 1 | 2009 | 640 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2009 | 708 | 0.060 |
Why?
|
Ambulatory Care | 1 | 2015 | 2771 | 0.060 |
Why?
|
Glucocorticoids | 1 | 2013 | 2163 | 0.060 |
Why?
|
Neurons | 1 | 2023 | 9443 | 0.050 |
Why?
|
Evidence-Based Medicine | 4 | 2014 | 3685 | 0.050 |
Why?
|
Etoposide | 1 | 2005 | 634 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2007 | 621 | 0.050 |
Why?
|
Immunotherapy | 6 | 2021 | 4649 | 0.050 |
Why?
|
In Situ Nick-End Labeling | 1 | 2004 | 609 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2014 | 12969 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 2803 | 0.050 |
Why?
|
Peptides | 4 | 2010 | 4338 | 0.050 |
Why?
|
Adolescent | 17 | 2017 | 88196 | 0.050 |
Why?
|
Tooth Diseases | 1 | 2003 | 74 | 0.050 |
Why?
|
DNA | 2 | 2013 | 7208 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 4 | 2008 | 8163 | 0.050 |
Why?
|
Models, Statistical | 2 | 2013 | 5078 | 0.050 |
Why?
|
Genetic Variation | 2 | 2016 | 6570 | 0.050 |
Why?
|
DNA Polymerase III | 1 | 2002 | 51 | 0.050 |
Why?
|
Dental Research | 1 | 2002 | 61 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 3396 | 0.050 |
Why?
|
Survival Rate | 4 | 2021 | 12698 | 0.050 |
Why?
|
Injections, Subcutaneous | 2 | 2009 | 678 | 0.050 |
Why?
|
Alveolar Ridge Augmentation | 1 | 2005 | 208 | 0.050 |
Why?
|
Gastrointestinal Tract | 1 | 2008 | 831 | 0.050 |
Why?
|
Leukemia, Lymphoid | 2 | 1981 | 310 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2007 | 1784 | 0.050 |
Why?
|
Interleukin-1 | 2 | 2008 | 1250 | 0.050 |
Why?
|
Anemia, Aplastic | 1 | 1983 | 228 | 0.050 |
Why?
|
Neutropenia | 2 | 2004 | 884 | 0.050 |
Why?
|
Sialoglycoproteins | 1 | 2002 | 315 | 0.050 |
Why?
|
Receptors, Interleukin-1 | 1 | 2002 | 262 | 0.050 |
Why?
|
Neutrophils | 10 | 1983 | 3764 | 0.050 |
Why?
|
Thrombocytopenia | 1 | 2009 | 1174 | 0.050 |
Why?
|
Immunoblotting | 1 | 2004 | 1647 | 0.050 |
Why?
|
DNA, Bacterial | 1 | 2006 | 1481 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2017 | 10425 | 0.050 |
Why?
|
Leukocytes | 2 | 1979 | 2024 | 0.050 |
Why?
|
Immune Sera | 3 | 1976 | 613 | 0.050 |
Why?
|
Lymphocytes | 8 | 1983 | 2610 | 0.050 |
Why?
|
Chronic Disease | 1 | 2016 | 9309 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2002 | 512 | 0.050 |
Why?
|
Weight Loss | 3 | 1997 | 2683 | 0.050 |
Why?
|
Recombinant Proteins | 5 | 2011 | 6525 | 0.040 |
Why?
|
Opportunistic Infections | 2 | 1998 | 376 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2005 | 1703 | 0.040 |
Why?
|
Administration, Buccal | 1 | 2019 | 13 | 0.040 |
Why?
|
Jejunum | 3 | 2008 | 472 | 0.040 |
Why?
|
Genes | 1 | 2004 | 1844 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 2217 | 0.040 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2002 | 398 | 0.040 |
Why?
|
Seasons | 1 | 2006 | 1518 | 0.040 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6813 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2005 | 2218 | 0.040 |
Why?
|
Mice, Nude | 2 | 2016 | 3603 | 0.040 |
Why?
|
Databases, Factual | 1 | 1995 | 7948 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2002 | 425 | 0.040 |
Why?
|
Bacteria | 2 | 2006 | 2217 | 0.040 |
Why?
|
Medicare | 1 | 2017 | 6732 | 0.040 |
Why?
|
Nitric Oxide Synthase | 1 | 2002 | 906 | 0.040 |
Why?
|
Tablets | 1 | 2019 | 147 | 0.040 |
Why?
|
Dentists | 1 | 2021 | 178 | 0.040 |
Why?
|
Disease Progression | 3 | 2008 | 13484 | 0.040 |
Why?
|
Young Adult | 6 | 2019 | 59068 | 0.040 |
Why?
|
Keratosis | 2 | 1978 | 80 | 0.040 |
Why?
|
Biguanides | 1 | 1978 | 21 | 0.040 |
Why?
|
Narcotics | 1 | 2001 | 336 | 0.040 |
Why?
|
Keratins | 1 | 2000 | 497 | 0.040 |
Why?
|
Ontario | 1 | 2019 | 399 | 0.040 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2014 | 374 | 0.040 |
Why?
|
Facial Pain | 2 | 2008 | 120 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2007 | 3512 | 0.040 |
Why?
|
Streptococcus | 3 | 1999 | 198 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2023 | 1257 | 0.040 |
Why?
|
Radiometry | 1 | 2023 | 813 | 0.040 |
Why?
|
Mandible | 1 | 2003 | 753 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2008 | 11900 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2021 | 422 | 0.040 |
Why?
|
Deglutition Disorders | 2 | 2019 | 627 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 1979 | 303 | 0.040 |
Why?
|
Observer Variation | 2 | 2005 | 2604 | 0.040 |
Why?
|
Platelet Count | 2 | 1995 | 780 | 0.040 |
Why?
|
Chlorhexidine | 1 | 1978 | 160 | 0.040 |
Why?
|
Mycoses | 3 | 2006 | 386 | 0.040 |
Why?
|
Mice, Inbred BALB C | 8 | 2014 | 6206 | 0.040 |
Why?
|
Mice, Inbred C57BL | 10 | 2013 | 22121 | 0.040 |
Why?
|
Prostaglandins E | 1 | 1977 | 169 | 0.040 |
Why?
|
Stomatitis, Herpetic | 1 | 1996 | 12 | 0.030 |
Why?
|
Anti-Infective Agents, Local | 1 | 1999 | 247 | 0.030 |
Why?
|
Solutions | 1 | 2017 | 411 | 0.030 |
Why?
|
Oxygen | 1 | 2008 | 4222 | 0.030 |
Why?
|
Hospitals, General | 1 | 2021 | 798 | 0.030 |
Why?
|
Benz(a)Anthracenes | 1 | 1975 | 11 | 0.030 |
Why?
|
Morbidity | 1 | 1982 | 1750 | 0.030 |
Why?
|
Cheek | 2 | 2008 | 65 | 0.030 |
Why?
|
Deficiency Diseases | 1 | 1996 | 74 | 0.030 |
Why?
|
Dental Staff, Hospital | 1 | 2015 | 2 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1997 | 283 | 0.030 |
Why?
|
Familial Mediterranean Fever | 1 | 1996 | 65 | 0.030 |
Why?
|
Antimicrobial Cationic Peptides | 3 | 2003 | 353 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2002 | 1753 | 0.030 |
Why?
|
Behcet Syndrome | 1 | 1996 | 86 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2021 | 1119 | 0.030 |
Why?
|
Education, Dental, Graduate | 1 | 2015 | 48 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2006 | 2633 | 0.030 |
Why?
|
Lymphoma | 3 | 2003 | 1901 | 0.030 |
Why?
|
Cytarabine | 1 | 1977 | 697 | 0.030 |
Why?
|
Mice, Inbred C3H | 1 | 2016 | 915 | 0.030 |
Why?
|
Antigens, Neoplasm | 3 | 1984 | 1994 | 0.030 |
Why?
|
Faculty, Dental | 1 | 2015 | 59 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 1996 | 449 | 0.030 |
Why?
|
Internship and Residency | 1 | 2015 | 5866 | 0.030 |
Why?
|
Mast Cells | 2 | 2000 | 1391 | 0.030 |
Why?
|
Alveoloplasty | 2 | 1985 | 22 | 0.030 |
Why?
|
Republic of Korea | 1 | 2017 | 571 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 1999 | 2852 | 0.030 |
Why?
|
Sucralfate | 1 | 2014 | 12 | 0.030 |
Why?
|
Private Practice | 1 | 2015 | 152 | 0.030 |
Why?
|
Mink | 1 | 1994 | 31 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2006 | 2572 | 0.030 |
Why?
|
Schools, Dental | 1 | 2015 | 123 | 0.030 |
Why?
|
Lymphocyte Activation | 6 | 1983 | 5491 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 1996 | 819 | 0.030 |
Why?
|
Child | 13 | 2021 | 80086 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2014 | 1649 | 0.030 |
Why?
|
Palate | 2 | 1987 | 124 | 0.030 |
Why?
|
Pain Measurement | 3 | 2011 | 3546 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2019 | 2927 | 0.030 |
Why?
|
Bone Marrow Cells | 3 | 1997 | 2416 | 0.030 |
Why?
|
Education, Medical | 1 | 2005 | 1726 | 0.030 |
Why?
|
Staff Development | 1 | 2015 | 228 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2004 | 2642 | 0.030 |
Why?
|
Fibroblasts | 1 | 2004 | 4106 | 0.030 |
Why?
|
Computer Communication Networks | 1 | 1995 | 294 | 0.030 |
Why?
|
Personnel Selection | 1 | 2015 | 195 | 0.030 |
Why?
|
Rats, Zucker | 1 | 2013 | 131 | 0.030 |
Why?
|
Collagen | 2 | 2014 | 2637 | 0.030 |
Why?
|
Root Canal Therapy | 1 | 1993 | 66 | 0.030 |
Why?
|
Coloring Agents | 2 | 2007 | 559 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10180 | 0.030 |
Why?
|
Interleukin-4 | 1 | 1996 | 1130 | 0.030 |
Why?
|
Cytotoxicity Tests, Immunologic | 4 | 1978 | 321 | 0.030 |
Why?
|
Skin Ulcer | 1 | 2014 | 129 | 0.030 |
Why?
|
Dermis | 1 | 2014 | 202 | 0.030 |
Why?
|
Documentation | 1 | 1999 | 895 | 0.030 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 1996 | 557 | 0.030 |
Why?
|
Spleen | 4 | 1983 | 2296 | 0.030 |
Why?
|
Pilot Projects | 4 | 2009 | 8611 | 0.030 |
Why?
|
Mice, Obese | 1 | 2013 | 420 | 0.030 |
Why?
|
Infusion Pumps, Implantable | 1 | 1992 | 158 | 0.020 |
Why?
|
Hair Follicle | 1 | 2014 | 211 | 0.020 |
Why?
|
BCG Vaccine | 1 | 1975 | 369 | 0.020 |
Why?
|
Receptor, Cholecystokinin B | 1 | 2011 | 6 | 0.020 |
Why?
|
Salivary Gland Neoplasms | 1 | 1975 | 304 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2002 | 2911 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 712 | 0.020 |
Why?
|
Prevotella melaninogenica | 1 | 1991 | 13 | 0.020 |
Why?
|
Pterygoid Muscles | 1 | 1991 | 9 | 0.020 |
Why?
|
Haemophilus | 1 | 1991 | 28 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2013 | 39078 | 0.020 |
Why?
|
Cytoprotection | 1 | 2012 | 199 | 0.020 |
Why?
|
Comorbidity | 1 | 2006 | 10494 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 1996 | 855 | 0.020 |
Why?
|
Episode of Care | 1 | 1992 | 127 | 0.020 |
Why?
|
Mandibular Nerve | 1 | 1991 | 61 | 0.020 |
Why?
|
CHO Cells | 1 | 1994 | 1389 | 0.020 |
Why?
|
Epidermis | 1 | 2014 | 528 | 0.020 |
Why?
|
Salivary Glands | 2 | 2003 | 229 | 0.020 |
Why?
|
Adherens Junctions | 1 | 2011 | 89 | 0.020 |
Why?
|
Phototherapy | 1 | 2014 | 368 | 0.020 |
Why?
|
Obesity | 1 | 2013 | 12918 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2002 | 3609 | 0.020 |
Why?
|
Hair | 1 | 2014 | 497 | 0.020 |
Why?
|
Quinazolines | 1 | 2017 | 1371 | 0.020 |
Why?
|
Operating Rooms | 1 | 1996 | 790 | 0.020 |
Why?
|
Rats, Inbred Strains | 2 | 2008 | 2090 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2017 | 22097 | 0.020 |
Why?
|
Complement System Proteins | 3 | 1980 | 788 | 0.020 |
Why?
|
Colon | 2 | 2008 | 1791 | 0.020 |
Why?
|
Clinical Competence | 1 | 2005 | 4777 | 0.020 |
Why?
|
Immunity | 1 | 1975 | 997 | 0.020 |
Why?
|
Leukopenia | 1 | 1990 | 213 | 0.020 |
Why?
|
Gene Expression | 1 | 2002 | 7582 | 0.020 |
Why?
|
Placebo Effect | 1 | 2013 | 518 | 0.020 |
Why?
|
Brain | 1 | 2016 | 27060 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1850 | 0.020 |
Why?
|
Fever | 1 | 1996 | 1618 | 0.020 |
Why?
|
Career Choice | 1 | 2015 | 755 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2004 | 14397 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 12127 | 0.020 |
Why?
|
Hydroxyapatites | 1 | 1988 | 73 | 0.020 |
Why?
|
Analgesics, Opioid | 2 | 2019 | 3792 | 0.020 |
Why?
|
Patients | 1 | 2015 | 905 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 5491 | 0.020 |
Why?
|
Blood Platelets | 1 | 1979 | 2478 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2014 | 12785 | 0.020 |
Why?
|
Risk | 1 | 2020 | 9605 | 0.020 |
Why?
|
Virus Diseases | 2 | 1991 | 719 | 0.020 |
Why?
|
Patient Discharge | 1 | 2001 | 3436 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8826 | 0.020 |
Why?
|
Hematoxylin | 1 | 2007 | 60 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 1976 | 2385 | 0.020 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2007 | 69 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3590 | 0.020 |
Why?
|
Chromium Radioisotopes | 2 | 1979 | 34 | 0.020 |
Why?
|
Neoplasm Transplantation | 3 | 1976 | 2014 | 0.020 |
Why?
|
Creatinine | 1 | 2013 | 1898 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3874 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2008 | 260 | 0.020 |
Why?
|
Simplexvirus | 1 | 1990 | 803 | 0.020 |
Why?
|
Glucose | 3 | 2013 | 4342 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2011 | 2468 | 0.020 |
Why?
|
Analgesics | 1 | 2014 | 1070 | 0.020 |
Why?
|
Candidiasis, Oral | 2 | 1993 | 57 | 0.020 |
Why?
|
Program Evaluation | 1 | 2015 | 2493 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2004 | 7849 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 7380 | 0.020 |
Why?
|
Linear Models | 1 | 1996 | 5865 | 0.020 |
Why?
|
Treatment Failure | 2 | 2003 | 2642 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2019 | 4026 | 0.020 |
Why?
|
Carboplatin | 1 | 2009 | 793 | 0.020 |
Why?
|
Eating | 1 | 2013 | 1535 | 0.020 |
Why?
|
Carotenoids | 1 | 1989 | 621 | 0.020 |
Why?
|
Cell Cycle | 1 | 1994 | 2929 | 0.020 |
Why?
|
Diet | 1 | 2004 | 8058 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7817 | 0.020 |
Why?
|
Mitogens | 2 | 1983 | 230 | 0.020 |
Why?
|
Glutamine | 1 | 2008 | 576 | 0.020 |
Why?
|
Hodgkin Disease | 2 | 2006 | 1378 | 0.020 |
Why?
|
Dietary Fats | 1 | 2013 | 1994 | 0.020 |
Why?
|
Benzodiazepines | 1 | 2011 | 1130 | 0.020 |
Why?
|
Plant Extracts | 1 | 1989 | 497 | 0.020 |
Why?
|
Gingival Neoplasms | 1 | 1984 | 20 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13240 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2013 | 1899 | 0.010 |
Why?
|
Bone Matrix | 1 | 2005 | 118 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2016 | 13445 | 0.010 |
Why?
|
Ameloblastoma | 1 | 1984 | 42 | 0.010 |
Why?
|
Hospitals | 1 | 2017 | 3873 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2011 | 2189 | 0.010 |
Why?
|
Rats, Inbred Lew | 2 | 1976 | 1155 | 0.010 |
Why?
|
Antibody Specificity | 2 | 1976 | 1060 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2005 | 642 | 0.010 |
Why?
|
Age of Onset | 1 | 2010 | 3302 | 0.010 |
Why?
|
Durapatite | 1 | 2005 | 163 | 0.010 |
Why?
|
Health Status | 1 | 1996 | 4071 | 0.010 |
Why?
|
Powders | 1 | 1983 | 80 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2016 | 17639 | 0.010 |
Why?
|
Child, Preschool | 6 | 2002 | 42209 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 1996 | 12054 | 0.010 |
Why?
|
Bromodeoxyuridine | 1 | 2003 | 311 | 0.010 |
Why?
|
Radionuclide Imaging | 2 | 2003 | 1975 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 2004 | 6297 | 0.010 |
Why?
|
Gingival Diseases | 2 | 1980 | 36 | 0.010 |
Why?
|
Dental Pulp Diseases | 1 | 1982 | 12 | 0.010 |
Why?
|
International Agencies | 1 | 2003 | 243 | 0.010 |
Why?
|
Human Genome Project | 1 | 2003 | 200 | 0.010 |
Why?
|
Anti-Bacterial Agents | 2 | 2003 | 7424 | 0.010 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 891 | 0.010 |
Why?
|
DNA, Circular | 1 | 2002 | 97 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 1874 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2004 | 719 | 0.010 |
Why?
|
Suburban Population | 1 | 1982 | 53 | 0.010 |
Why?
|
Porosity | 1 | 2003 | 350 | 0.010 |
Why?
|
Radiography | 1 | 1993 | 6963 | 0.010 |
Why?
|
Paclitaxel | 1 | 2009 | 1732 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3800 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4567 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14661 | 0.010 |
Why?
|
Cell Line | 3 | 2012 | 15598 | 0.010 |
Why?
|
Prostheses and Implants | 1 | 1988 | 1272 | 0.010 |
Why?
|
Brain Abscess | 1 | 1982 | 120 | 0.010 |
Why?
|
Alveolar Bone Loss | 1 | 2005 | 390 | 0.010 |
Why?
|
Glycogen | 1 | 1982 | 251 | 0.010 |
Why?
|
Acute Disease | 2 | 2002 | 7230 | 0.010 |
Why?
|
Acyclovir | 2 | 1993 | 268 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3880 | 0.010 |
Why?
|
Cavernous Sinus | 1 | 1982 | 123 | 0.010 |
Why?
|
Antibody Formation | 2 | 1976 | 1397 | 0.010 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 1982 | 110 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1983 | 1627 | 0.010 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 299 | 0.010 |
Why?
|
Particle Size | 1 | 2005 | 1643 | 0.010 |
Why?
|
Dogs | 1 | 1985 | 3839 | 0.010 |
Why?
|
Bone Marrow Diseases | 1 | 1982 | 232 | 0.010 |
Why?
|
Body Fluids | 1 | 2002 | 319 | 0.010 |
Why?
|
Isotretinoin | 1 | 1981 | 133 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2014 | 7597 | 0.010 |
Why?
|
Hexosephosphates | 1 | 1979 | 26 | 0.010 |
Why?
|
Periapical Tissue | 1 | 1979 | 10 | 0.010 |
Why?
|
Rosette Formation | 1 | 1979 | 152 | 0.010 |
Why?
|
Colitis | 2 | 1994 | 1230 | 0.010 |
Why?
|
Random Allocation | 2 | 1988 | 2388 | 0.010 |
Why?
|
Pasteurella | 1 | 1999 | 6 | 0.010 |
Why?
|
Cattle | 1 | 1985 | 3849 | 0.010 |
Why?
|
Proteus mirabilis | 1 | 1999 | 25 | 0.010 |
Why?
|
Radiation Protection | 1 | 2003 | 424 | 0.010 |
Why?
|
Submandibular Gland | 1 | 1979 | 87 | 0.010 |
Why?
|
Multiple Organ Failure | 1 | 2002 | 386 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 2007 | 1900 | 0.010 |
Why?
|
Heart Diseases | 2 | 1983 | 2785 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2002 | 582 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 16945 | 0.010 |
Why?
|
Sialadenitis | 1 | 1979 | 45 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2012 | 3541 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 1996 | 10188 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2006 | 1373 | 0.010 |
Why?
|
Bacillus | 1 | 1999 | 78 | 0.010 |
Why?
|
Colony Count, Microbial | 1 | 1999 | 330 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2002 | 1900 | 0.010 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1983 | 1445 | 0.010 |
Why?
|
Hyperplasia | 1 | 1981 | 1153 | 0.010 |
Why?
|
Biopsy | 2 | 2009 | 6765 | 0.010 |
Why?
|
Curriculum | 1 | 1991 | 3732 | 0.010 |
Why?
|
Longitudinal Studies | 2 | 2010 | 14565 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2009 | 5236 | 0.010 |
Why?
|
Teaching | 1 | 2005 | 1169 | 0.010 |
Why?
|
Kidney | 1 | 2013 | 7046 | 0.010 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 1979 | 280 | 0.010 |
Why?
|
Liver | 1 | 2013 | 7531 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1977 | 184 | 0.010 |
Why?
|
Chromatography, Thin Layer | 1 | 1977 | 213 | 0.010 |
Why?
|
Cells, Cultured | 5 | 1984 | 18955 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 1980 | 1351 | 0.010 |
Why?
|
Atrophy | 1 | 1981 | 1631 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1979 | 1704 | 0.010 |
Why?
|
Indomethacin | 1 | 1977 | 326 | 0.010 |
Why?
|
Antigen-Antibody Reactions | 1 | 1976 | 346 | 0.010 |
Why?
|
Mice, Inbred CBA | 1 | 1996 | 436 | 0.010 |
Why?
|
Graft Survival | 2 | 2004 | 3806 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 1975 | 306 | 0.010 |
Why?
|
Crohn Disease | 2 | 1979 | 2278 | 0.010 |
Why?
|
Adhesiveness | 1 | 1975 | 52 | 0.010 |
Why?
|
Injections, Intraperitoneal | 1 | 1975 | 412 | 0.010 |
Why?
|
Species Specificity | 2 | 1979 | 2417 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 1975 | 248 | 0.010 |
Why?
|
Sex Factors | 1 | 2009 | 10538 | 0.010 |
Why?
|
Antibodies, Neoplasm | 1 | 1976 | 281 | 0.010 |
Why?
|
Culture Media | 1 | 1977 | 899 | 0.010 |
Why?
|
Tooth Extraction | 2 | 1988 | 229 | 0.010 |
Why?
|
HLA-B27 Antigen | 1 | 1994 | 63 | 0.010 |
Why?
|
Acetic Acid | 1 | 1994 | 60 | 0.010 |
Why?
|
Cytoplasm | 1 | 1978 | 1511 | 0.010 |
Why?
|
Urban Population | 1 | 1982 | 2032 | 0.010 |
Why?
|
Palliative Care | 1 | 2008 | 3585 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 1979 | 1411 | 0.010 |
Why?
|
Infant | 3 | 1988 | 36183 | 0.010 |
Why?
|
beta 2-Microglobulin | 1 | 1994 | 329 | 0.010 |
Why?
|
Drug Hypersensitivity | 1 | 1982 | 917 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 1994 | 825 | 0.010 |
Why?
|
Tissue Donors | 1 | 2002 | 2319 | 0.010 |
Why?
|
Mental Disorders | 2 | 1983 | 6831 | 0.010 |
Why?
|
Acetates | 1 | 1994 | 321 | 0.010 |
Why?
|
Streptococcaceae | 1 | 1971 | 4 | 0.010 |
Why?
|
Micrococcus | 1 | 1971 | 13 | 0.010 |
Why?
|
Neisseria | 1 | 1971 | 12 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1986 | 4226 | 0.010 |
Why?
|
Drug Resistance | 1 | 1977 | 1597 | 0.010 |
Why?
|
Staphylococcus | 1 | 1971 | 156 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 1982 | 2757 | 0.010 |
Why?
|
Cell-Free System | 2 | 1983 | 340 | 0.010 |
Why?
|
Cell Survival | 2 | 1977 | 5790 | 0.010 |
Why?
|
Graft Rejection | 1 | 1983 | 4438 | 0.010 |
Why?
|
Hemorrhage | 1 | 1982 | 3414 | 0.010 |
Why?
|
Escherichia coli | 2 | 1999 | 4234 | 0.010 |
Why?
|
Cell Nucleus | 1 | 1978 | 2906 | 0.010 |
Why?
|
Rectal Neoplasms | 1 | 1978 | 1157 | 0.010 |
Why?
|
Mice, Inbred Strains | 2 | 1983 | 1759 | 0.000 |
Why?
|
Animals, Genetically Modified | 1 | 1994 | 1561 | 0.000 |
Why?
|
Serologic Tests | 1 | 1990 | 384 | 0.000 |
Why?
|
Antifungal Agents | 1 | 1993 | 751 | 0.000 |
Why?
|
beta Carotene | 1 | 1989 | 523 | 0.000 |
Why?
|
Freund's Adjuvant | 1 | 1987 | 148 | 0.000 |
Why?
|
Antibodies | 1 | 1975 | 2421 | 0.000 |
Why?
|
Colitis, Ulcerative | 1 | 1979 | 1922 | 0.000 |
Why?
|
Colonic Neoplasms | 1 | 1978 | 2529 | 0.000 |
Why?
|
Blood Glucose | 1 | 1979 | 6380 | 0.000 |
Why?
|
Age Factors | 1 | 1981 | 18379 | 0.000 |
Why?
|
Phagocytosis | 2 | 1982 | 1536 | 0.000 |
Why?
|
Actinomyces | 1 | 1983 | 40 | 0.000 |
Why?
|
Antibody-Producing Cells | 1 | 1983 | 140 | 0.000 |
Why?
|
Ascitic Fluid | 1 | 1983 | 189 | 0.000 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 1983 | 516 | 0.000 |
Why?
|
Thioglycolates | 1 | 1982 | 38 | 0.000 |
Why?
|
Neck | 1 | 1986 | 735 | 0.000 |
Why?
|
Metaplasia | 1 | 1981 | 321 | 0.000 |
Why?
|
Phytohemagglutinins | 1 | 1979 | 168 | 0.000 |
Why?
|
Pregnancy | 1 | 2001 | 29831 | 0.000 |
Why?
|
Thymidine | 1 | 1979 | 299 | 0.000 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1994 | 2419 | 0.000 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1979 | 365 | 0.000 |
Why?
|
Bacteriolysis | 1 | 1978 | 51 | 0.000 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1983 | 973 | 0.000 |
Why?
|
Idoxuridine | 1 | 1977 | 111 | 0.000 |
Why?
|
Leukemia, Myeloid | 1 | 1980 | 694 | 0.000 |
Why?
|
Cell Adhesion | 1 | 1983 | 3088 | 0.000 |
Why?
|
Thymus Gland | 1 | 1982 | 1241 | 0.000 |
Why?
|
Carcinoembryonic Antigen | 1 | 1978 | 337 | 0.000 |
Why?
|
Necrosis | 1 | 1981 | 1604 | 0.000 |
Why?
|
Freezing | 1 | 1977 | 310 | 0.000 |
Why?
|
Isotope Labeling | 1 | 1977 | 393 | 0.000 |
Why?
|
Skin Transplantation | 1 | 1980 | 1083 | 0.000 |
Why?
|
Lipopolysaccharides | 1 | 1982 | 2205 | 0.000 |
Why?
|
Blood Transfusion | 1 | 1980 | 1299 | 0.000 |
Why?
|
Prednisone | 1 | 1978 | 1564 | 0.000 |
Why?
|
Intestinal Diseases | 1 | 1978 | 504 | 0.000 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1978 | 926 | 0.000 |
Why?
|
Liver Neoplasms | 1 | 1984 | 4319 | 0.000 |
Why?
|
Cell Differentiation | 1 | 1983 | 11526 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 1978 | 6330 | 0.000 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1978 | 9267 | 0.000 |
Why?
|